Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses

被引:12
作者
Shi, Zhenguo [1 ,2 ]
Zhu, Xiaojuan [2 ]
Ke, Shaobo [1 ]
Qiu, Hu [1 ]
Cai, Gaoke [1 ]
Zhangcai, Yutian [1 ]
Chen, Yongshun [1 ]
机构
[1] Wuhan Univ, Dept Clin Oncol, Renmin Hosp, Wuhan, Peoples R China
[2] Henan Univ Sci & Technol, Dept Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
基金
中国国家自然科学基金;
关键词
Elderly patients; Synchronous oligometastatic esophageal; squamous cell carcinoma; Concurrent chemoradiotherapy; Survival; Nomogram; CLINICOPATHOLOGICAL CHARACTERISTICS; NEOADJUVANT CHEMORADIOTHERAPY; RADIATION-THERAPY; CANCER; RADIOTHERAPY; ONCOLOGY; CHEMOTHERAPY; MANAGEMENT; OUTCOMES; DISEASE;
D O I
10.1016/j.radonc.2021.09.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the potential benefits of concurrent chemoradiotherapy (CCRT), and to establish a nomogram for predicting survival outcomes of elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma (SOEC). Materials and methods: This study eventually enrolled 314 elderly patients who initially diagnosed with SOEC from two centers. Treatment responses and outcomes of 151 patients receiving CCRT and 163 patients undergoing chemotherapy alone (CT) were compared. Propensity score matching and landmark analyses were performed to control potential confounding factors. A nomogram was established on the basis of the Cox regression model. Results: After a median follow-up of 42.3 months, CCRT was superior to CT alone in objective response rate (ORR, 59.6% vs. 39.9%, P < 0.001), median progression-free survival (PFS, 10.0 vs. 7.2 months, P < 0.001), and median overall survival (OS, 18.5 vs. 15.6 months, P < 0.001). The propensity score matching (PSM) and landmark analyses redemonstrated the same trend (P < 0.01). On hierarchical analysis, patients with 1- 3 metastatic lesions involving one organ displayed longer median PFS (9.0 vs. 7.8 months, P = 0.008) and OS (17.8 vs. 15.2 months, P < 0.001) than those with 4-5 metastatic lesions involving 2-3 organs. The major toxicities of grade III or higher for CCRT included leukocytopenia (23.2%), radiation esophagitis (7.3%), and radiation pneumonitis (8.6%). Cox multivariate analysis showed that the number of metastatic lesions (P = 0.012) and tumor response (P < 0.001) were independent prognostic factors associated with OS. A nomogram was established by incorporating the number of metastatic lesions and tumor response, with a concordance index of 0.743 after internal cross-validation. Calibration curves and decision curve analysis confirmed that nomogram had a favorable predictive value for individualized survival. Conclusions: Compared with CT alone, CCRT exhibited superior efficacy and acceptable toxicity in the first line treatment for elderly patients with SOEC. The current study supports the oligometastatic definition of <3 metastatic lesions involving one organ for esophageal cancer patients. The constructed nomogram can effectively predict the individualized survival. (c) 2021 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 164 (2021) 236-244
引用
收藏
页码:236 / 244
页数:9
相关论文
共 50 条
  • [31] Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients
    Zhang, Haowen
    Xiao, Xin
    Luan, Siyuan
    Li, Xiaokun
    Sun, Shangwei
    Yuan, Yong
    SAUDI MEDICAL JOURNAL, 2024, 45 (05) : 481 - 489
  • [32] Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan
    Chen, Hui-Shan
    Hung, Wei-Heng
    Ko, Jiunn-Liang
    Hsu, Po-Kuei
    Liu, Chia-Chuan
    Wu, Shiao-Chi
    Lin, Ching-Hsiung
    Wang, Bing-Yen
    MEDICINE, 2016, 95 (10)
  • [33] Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy
    Shi, Yujing
    Shen, Gefenqiang
    Zeng, Yuting
    Ju, Mengyang
    Chen, Xiaojiao
    He, Chenhong
    Liang, Liang
    Ge, Xiaolin
    Sun, Xinchen
    Di, Xiaoke
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 123
  • [34] Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
    Chen, Chih-Yi
    Li, Chia-Chin
    Chien, Chun-Ru
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [35] Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study
    Zhai, Y.
    Hui, Z.
    Wang, J.
    Zou, S.
    Liang, J.
    Wang, X.
    Lv, J.
    Chen, B.
    Zhu, H.
    Wang, L.
    DISEASES OF THE ESOPHAGUS, 2013, 26 (05): : 503 - 509
  • [36] Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
    Zhao, Junfeng
    Hao, Shaoyu
    Tian, Jing
    Li, Ying
    Han, Dan
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 3351 - 3363
  • [37] A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy
    Wang, Peiliang
    Yang, Maoqi
    Wang, Xin
    Zhao, Zongxing
    Li, Minghuan
    Yu, Jinming
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (03)
  • [38] Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study
    Liu, Di-Han
    Zhou, Xiao-Yu
    Pan, You-Guang
    Chen, Si
    Ye, Zheng-Hao
    Chen, Gang-Dung
    CANCER MEDICINE, 2020, 9 (04): : 1287 - 1297
  • [39] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [40] The Clinical Outcomes of Locally Advanced Cervical Esophageal Squamous Cell Carcinoma Patients Receiving Curative Concurrent Chemoradiotherapy: A Population-Based Propensity Score-Matched Analysis
    Chen, Yen-Hao
    Lu, Hung-, I
    Lo, Chien-Ming
    Wang, Yu-Ming
    Chou, Shang-Yu
    Hsiao, Chang-Chun
    Li, Shau-Hsuan
    CANCERS, 2019, 11 (04):